Mylan NV (MYL)

43.15
2.47 5.41
NASDAQ : Health Care
Prev Close 45.62
Open 45.50
Day Low/High 42.78 / 45.99
52 Wk Low/High 37.59 / 55.51
Volume 17.90M
Avg Volume 4.53M
Exchange NASDAQ
Shares Outstanding 534.91M
Market Cap 25.62B
EPS 1.80
P/E Ratio 29.94
Div & Yield N.A. (N.A)

Latest News

Ugly Underlying Action Should Stay Hidden

Market momentum cools, big time.

Closing Bell: Clinton Calls Out Mylan on Price Hikes; U.S. Stock Losses Grow

Closing Bell: Clinton Calls Out Mylan on Price Hikes; U.S. Stock Losses Grow

U.S. stock losses grew heavier Wednesday as the afternoon wore-on with a selloff in crude oil and health care stocks leading Wall Street into the red.

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Mylan Falls After Being Called Out on Price Increases -- Should You Worry?

Shares of the world's second largest generic pharma company fell nearly 5% after U.S. politicians target company for price gouging.

Crude Oil, Health Care Team Up to Pull Wall Street Lower

Crude Oil, Health Care Team Up to Pull Wall Street Lower

A selloff in crude oil and health care stocks led Wall Street into the red on Wednesday.

Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again

Hillary Clinton Blasts Drug Prices, Biotech Stocks Plunge; Yes, It Could Be Happening Again

The Nasdaq Biotechnology Index fell 3.5% heading into Wednesday's close, with the loss triggered by a statement from Clinton's presidential campaign blasting Mylan for 'outrageous' pricing of the EpiPen.

Mylan Stock Unlikely to Bottom on Epipen Price Reduction

Mylan Stock Unlikely to Bottom on Epipen Price Reduction

Technical evidence shows bigger issues

More Squawk from Jim Cramer: Mylan (MYL) EpiPens 'Should Not Be Just for Rich People'

More Squawk from Jim Cramer: Mylan (MYL) EpiPens 'Should Not Be Just for Rich People'

Mylan (MYL) stock has slumped this week as the pharmaceutical company faces public criticism over the high price of its EpiPens.

BTIG's Chiang Explains on CNBC Why He's Sticking With Mylan (MYL)

BTIG's Chiang Explains on CNBC Why He's Sticking With Mylan (MYL)

BTIG managing director Tim Chiang joined CNBC's 'Power Lunch' Tuesday afternoon to explain the 'buy' rating he has on Mylan (MYL) shares.

Mylan (MYL) Stock Slides, Citigroup: EpiPen Scrutiny Could Drive Multiples Down

Mylan (MYL) Stock Slides, Citigroup: EpiPen Scrutiny Could Drive Multiples Down

Citigroup analysts say recent public scrutiny over Mylan's (MYL) EpiPen won't affect its earnings, but could 'weigh on the stock's multiple' in the near term.

A Backlash Materializes Against Soaring EpiPen Prices

A Backlash Materializes Against Soaring EpiPen Prices

Senators Grassley, Blumenthal and Klobuchar demand Mylan reduce the price of its dominant treatment for life-threatening allergies.

U.S. Senator Grassley Requests EpiPen Pricing Explanation From Mylan (MYL)

U.S. Senator Grassley Requests EpiPen Pricing Explanation From Mylan (MYL)

Iowa Senator Chuck Grassley has officially requested Myaln (MYL) explain its price increases for the EpiPen.

Mylan (MYL) Stock Slides on EpiPen Price Criticism

Mylan (MYL) Stock Slides on EpiPen Price Criticism

Prices of Mylan's (MYL) EpiPen have reportedly increased 450% since 2004.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ELP, FCB, FGBI, HMC, IRT, JACK, JCP, MYL, NMIH, OBAS, SEED Downgrades: ATNI, CXW, PFIN, RIC, WABC Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

Mylan's Time Leaning on EpiPens Is Rapidly Approaching an End

Mylan's Time Leaning on EpiPens Is Rapidly Approaching an End

The Pittsburgh-based pharmaceutical company has been steadily jacking up the price of the auto injectors since 2010 to bolster revenues.

Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors

Why Hendrickson-Led Perrigo Is A Good Bet For Long Term Investors

Despite cutting its full year guidance, the company continues to have a lot of potential upside.

Jim Cramer: Perrigo is Problematic

Jim Cramer: Perrigo is Problematic

Perrigo might have been in more of a decline than the market realized when it turned down Mylan's $26 billion offer for the company last year, says Jim Cramer.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

Stock futures are rising on Wednesday as investors consider earnings from Disney and retailers.

Mylan (MYL) Stock Slides in After-Hours Trading on Q2 Revenue Miss

Mylan (MYL) Stock Slides in After-Hours Trading on Q2 Revenue Miss

Mylan (MYL) stock was trading lower after-hours on Tuesday after reporting financial results for the 2016 second quarter.

Buy Mylan, Ride the Momentum

Buy Mylan, Ride the Momentum

The stock should break above the resistance line on its way to its December high of around $55, if it beats earnings expectations late Tuesday.

Mylan Completes Acquisition Of Meda

Mylan Completes Acquisition Of Meda

Tennis Legend Billie Jean King Wants to Make the Sport More Like Basketball

Tennis Legend Billie Jean King Wants to Make the Sport More Like Basketball

Tennis icon Billie Jean King co-founded World Team Tennis (WTT) in 1974 and the organization's intent resonates more today than ever before with tennis fans.

Here Are Two Reasons to Buy Mylan Now

Here Are Two Reasons to Buy Mylan Now

The stock is breaking out of consolidation patterns on multiple timeframes.

Meda Shareholders Representing Approximately 94% Of Meda Shares Accept Mylan Offer

Meda Shareholders Representing Approximately 94% Of Meda Shares Accept Mylan Offer

Mylan Has Declared the Offer Unconditional, with Settlement Expected to Occur on Aug. 5, 2016

Mylan's Weakness Shouldn't Last, So Buy Now

Mylan's Weakness Shouldn't Last, So Buy Now

An investor should make good money on any turn in the drug maker's business or in investor sentiment.